What is it about?
Pharmaceutical products can degrade, making them potentially less useful. Manufacturers need to monitor these types of degradation. This paper provides a short review of how researchers and manufacturers are addressing one type of degradation, called deamidation.
Featured Image
Why is it important?
More diverse strategies than ever are being employed in control of deamidation during biopharmaceutical manufacture. This paper provides a summary of these strategies, which may be useful to those in process development.
Read the Original
This page is a summary of: Protein deamidation in biopharmaceutical manufacture: understanding, control and impact, Journal of Chemical Technology & Biotechnology, December 2015, Wiley,
DOI: 10.1002/jctb.4850.
You can read the full text:
Contributors
The following have contributed to this page